文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

瑞马唑仑用于终末期肾病患者镇静的疗效与安全性:一项前瞻性随机对照临床试验

Efficacy and safety of remimazolam for sedation of patients with end-stage renal disease: a prospective, randomized controlled clinical trial.
PubMed 文献 · Trials · 2026-04-16

本研究为单中心、前瞻性、观察者盲法随机对照试验,计划纳入80例≥18岁拟行腹膜透析导管置入或拔除的终末期肾病患者,随机接受瑞马唑仑或右美托咪定镇静。主要结局为给药后10分钟内MOAA/S评分≤1的镇静成功率,次要结局包括镇静起效时间、术中体动、BIS维持区间时长、苏醒时间及不良事件等。

要点

  • 瑞马唑仑代谢不依赖肾功能,可能为终末期肾病患者提供更优镇静选择。
  • 主要结局为给药后10分钟内MOAA/S≤1的镇静成功率。
  • 需关注低血压等血流动力学不稳定及苏醒延迟等不良事件。

核心结论

  • 瑞马唑仑可能较右美托咪定在终末期肾病患者程序性镇静中具有更优的镇静疗效和安全性,但尚待本试验结果验证。

研究设计与样本

  • 单中心、前瞻性、观察者盲法随机对照试验,计划纳入80例≥18岁拟行腹膜透析导管置入或拔除的终末期肾病患者。

关键数值与推荐

  • 主要结局为给药后10分钟内达到MOAA/S评分≤1的镇静成功率。
  • 次要结局包括镇静起效时间、术中体动、麻醉维持期间BIS值<60或>80的持续时间、苏醒时间、不良事件发生率、术后恶心呕吐发生率及术后疼痛评分。

临床怎么用

  • 若试验证实瑞马唑仑优于右美托咪定,可为终末期肾病患者程序性镇静提供不依赖肾功能代谢的给药选择。

局限性

  • 单中心设计可能限制结果外推性。
  • 样本量计划为80例,统计效能可能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Procedural sedation in patients with end-stage renal disease (ESRD) is challenging due to impaired renal function, which affects drug metabolism and increases the risk of adverse events. Remimazolam, a novel ultrashort-acting intravenous sedative, offers rapid onset and clearance independent of renal function, making it a potential alternative to dexmedetomidine for sedation in this patient population. This study aims to compare the efficacy and safety of remimazolam versus dexmedetomidine in ESRD patients undergoing procedural sedation. The primary hypothesis is that remimazolam will demonstrate superior sedation efficacy and a better safety profile, with reduced hemodynamic instability and faster recovery. METHODS: This is a single-center, prospective, observer-blinded, randomized controlled trial (RCT). A total of 80 ESRD patients aged ≥ 18 years scheduled for peritoneal dialysis catheter placement or removal will be randomly assigned to receive either remimazolam or dexmedetomidine. The primary outcome is the sedation success rate, defined as achieving a Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score ≤ 1 within 10 min of drug administration. Secondary outcomes include time to sedation, intraoperative movements, the duration of BIS values < 60 or > 80 during anesthesia maintenance, recovery time, the incidence of adverse events, incidence of postoperative nausea and vomiting (PONV), and postoperative pain scores. DISCUSSION: This is the first RCT to directly compare remimazolam and dexmedetomidine for sedation in ESRD patients undergoing procedural sedation. The results of this study will provide valuable insights into optimizing sedation strategies in this high-risk population, potentially improving clinical outcomes by minimizing complications associated with drug metabolism and recovery. TRIAL REGISTRATION: Chinese Clinical Trial Registry. chictr.org.cn ChiCTR2300075278. Registered on August 31, 2023. https://www.chictr.org.cn/showproj.html?proj=205061 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Gao J, Yu H, Xu Z, et al. Efficacy and safety of remimazolam for sedation of patients with end-stage renal disease: a prospective, randomized controlled clinical trial. Trials. 2026. PMID: 41987330. doi:10.1186/s13063-026-09700-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。